Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults
Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of Direct Venous Inoculation of Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in HIV Negative and HIV Positive Tanzanian Adults
Sponsor: Ifakara Health Institute
Listed as NCT03420053, this PHASE1 trial focuses on Malaria and Malaria,Falciparum and remains completed. Sponsored by Ifakara Health Institute, it has been updated 9 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
May 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2018 — May 2019 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ifakara Health Institute
- Medical Care Development, Inc.
- Sanaria Inc.
- Swiss Tropical & Public Health Institute
For direct contact, visit the study record on ClinicalTrials.gov .